Apremilast – Treatment for Psoriasis

Apremilast is an oral small-molecule medication classified as a phosphodiesterase 4 (PDE4) inhibitor, used in the treatment of inflammatory conditions such as moderate to severe plaque psoriasis and psoriatic arthritis. By inhibiting the PDE4 enzyme, Apremilast increases intracellular cyclic adenosine monophosphate (cAMP) levels, which in turn reduces the production of pro-inflammatory cytokines while increasing anti-inflammatory mediators. This mechanism helps to control inflammation and reduce the symptoms associated with autoimmune and inflammatory skin and joint conditions. Apremilast offers an effective, non-biologic oral treatment option, providing flexibility and convenience in the management of chronic inflammatory diseases. It is generally well-tolerated and can improve quality of life for patients requiring long-term treatment under medical supervision.